Page 2 - Context Therapeutic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Analysts expect that Context Therapeutics Inc. (NASDAQ:CNTX – Get Rating) will post earnings per share of ($0.29) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Context Therapeutics’ earnings. The company is expected to announce its next earnings report on Monday, January 1st. According to Zacks, analysts expect that Context Therapeutics […]

Context Therapeutics’ (NASDAQ:CNTX – Get Rating) lock-up period will end on Monday, April 18th. Context Therapeutics had issued 5,000,000 shares in its public offering on October 20th. The total size of the offering was $25,000,000 based on an initial share price of $5.00. Shares of the company owned by company insiders and major shareholders will […]

02.12.2021 - PHILADELPHIA, Dec. 01, 2021 (GLOBE NEWSWIRE) - Context Therapeutics Inc. (Nasdaq: CNTX) ('Context Therapeutics' or the 'Company'), a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast and ... Seite 1